$PHIO
Phio Pharmaceuticals Corp

2015 Q4 Form 10-Q Financial Statement

#000119312515375630 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $16.00K
YoY Change -100.0% -100.0% -82.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $900.0K $770.0K $770.0K
YoY Change 18.42% 0.0% -17.2%
% of Gross Profit
Research & Development $1.720M $1.734M $1.459M
YoY Change 10.26% 18.85% 18.71%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $30.00K
YoY Change 0.0% -33.33% 0.0%
% of Gross Profit
Operating Expenses $2.620M $2.504M $2.225M
YoY Change 12.93% 12.54% 2.87%
Operating Profit -$2.504M -$2.209M
YoY Change 13.35% 6.66%
Interest Expense $10.00K $8.000K $4.000K
YoY Change 100.0% -60.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $8.000K $3.000K
YoY Change 166.67% 50.0%
Pretax Income -$2.620M -$2.500M -$2.210M
YoY Change 13.91% 13.12% 7.28%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.620M -$2.496M -$2.206M
YoY Change 13.91% 13.15% 7.14%
Net Earnings / Revenue -13787.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$262.0M -$250.0M -$913.7M
COMMON SHARES
Basic Shares Outstanding 65.35M shares 64.95M shares 16.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.62M $12.04M $10.13M
YoY Change 24.94% 18.85% -36.09%
Cash & Equivalents $5.117M $4.035M $5.130M
Short-Term Investments $5.500M $8.000M $5.000M
Other Short-Term Assets $360.0K $480.0K $560.0K
YoY Change -26.53% -14.29% 143.48%
Inventory
Prepaid Expenses $311.0K
Receivables
Other Receivables
Total Short-Term Assets $10.98M $12.52M $10.69M
YoY Change 22.14% 17.09% -33.52%
LONG-TERM ASSETS
Property, Plant & Equipment $163.0K $162.0K $193.0K
YoY Change -10.93% -16.06% 48.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $18.00K $18.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $181.0K $180.0K $211.0K
YoY Change -9.95% -14.69% 62.31%
TOTAL ASSETS
Total Short-Term Assets $10.98M $12.52M $10.69M
Total Long-Term Assets $181.0K $180.0K $211.0K
Total Assets $11.16M $12.70M $10.90M
YoY Change 21.44% 16.48% -32.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.163M $222.0K $137.0K
YoY Change 308.07% 62.04% -22.6%
Accrued Expenses $1.106M $1.443M $958.0K
YoY Change 10.38% 50.63% -5.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.269M $1.665M $1.156M
YoY Change 70.09% 44.03% -13.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.269M $1.665M $1.156M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.270M $1.670M $1.160M
YoY Change 70.68% 43.97% -13.56%
SHAREHOLDERS EQUITY
Retained Earnings -$57.11M -$54.49M -$44.58M
YoY Change 21.81% 22.23%
Common Stock $1.000K $6.000K $2.000K
YoY Change -50.0% 200.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.890M $11.03M $4.723M
YoY Change
Total Liabilities & Shareholders Equity $11.16M $12.70M $10.90M
YoY Change 21.44% 16.48% -32.76%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$2.620M -$2.496M -$2.206M
YoY Change 13.91% 13.15% 7.14%
Depreciation, Depletion And Amortization $20.00K $20.00K $30.00K
YoY Change 0.0% -33.33% 0.0%
Cash From Operating Activities -$1.580M -$1.970M -$1.760M
YoY Change -1.25% 11.93% 1.73%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $0.00 -$20.00K
YoY Change 100.0% -100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $2.500M $0.00 -$5.000M
YoY Change -50.0% -100.0%
Cash From Investing Activities $2.480M $0.00 -$5.010M
YoY Change -50.3% -100.0% 50000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 10.00K 0.000
YoY Change -733.33% -100.0%
NET CHANGE
Cash From Operating Activities -1.580M -1.970M -1.760M
Cash From Investing Activities 2.480M 0.000 -5.010M
Cash From Financing Activities 190.0K 10.00K 0.000
Net Change In Cash 1.090M -1.960M -6.770M
YoY Change -67.56% -71.05% 286.86%
FREE CASH FLOW
Cash From Operating Activities -$1.580M -$1.970M -$1.760M
Capital Expenditures -$20.00K $0.00 -$20.00K
Free Cash Flow -$1.560M -$1.970M -$1.740M
YoY Change -1.89% 13.22% 1.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65349121 shares
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.40
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5130000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3308761 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.06
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64949121 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2376045 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64949121 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.33
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12697000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
11032000
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65515000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
222000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1443000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54489000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1665000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2015Q3 us-gaap Assets
Assets
12697000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
162000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
12517000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
432000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4035000
CY2015Q3 us-gaap Short Term Investments
ShortTermInvestments
8000000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11390000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3000264 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.39
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21984272 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21984272 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
2745000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48047000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
47000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
285000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1002000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46882000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9189000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1334000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8496000
CY2015Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9200000
CY2015Q2 rxii Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
10400000
CY2015Q2 rxii Sale Of Unit Number Of Shares
SaleOfUnitNumberOfShares
26000000 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2014Q4 us-gaap Assets
Assets
9189000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
183000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
8988000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
442000
CY2015Q2 rxii Sale Of Unit Description Of Transaction
SaleOfUnitDescriptionOfTransaction
Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the "Overallotment Purchase Rights") and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the "Warrants").
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6163000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19735374 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0701 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0160 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0273 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0150 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9791 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14726417 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Net Income Loss
NetIncomeLoss
-6496000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10164000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15000
us-gaap Revenue From Grants
RevenueFromGrants
57000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
207000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6520000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
10000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3668000
us-gaap Share Based Compensation
ShareBasedCompensation
1402000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
447000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
30000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-57000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6260000
us-gaap Operating Expenses
OperatingExpenses
6577000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2074000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
3000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1977000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4118000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1947000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-837000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2459000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3582000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000
rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
71000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5735000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
81667 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
35000 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29278376 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1681 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.55
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
390164 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.41
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0243 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8943 pure
dei Trading Symbol
TradingSymbol
RXII
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8529 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44451927 shares
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9313000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5202000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6814000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64949121 shares
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-63000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9266000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
441000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2447000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
us-gaap Net Income Loss
NetIncomeLoss
-7607000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7816000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10000
us-gaap Revenue From Grants
RevenueFromGrants
34000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7615000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
8000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
209000
us-gaap Share Based Compensation
ShareBasedCompensation
1243000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
126000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
31000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-47000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4461000
us-gaap Operating Expenses
OperatingExpenses
7649000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8039000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
228000
rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
-18700
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0252 pure
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0347 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.71
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0347 pure
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17494109 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-2206000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2906000
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
16000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2209000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000
CY2014Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
700000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
454000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
2225000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1459000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
766000
CY2014Q3 rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
24000
CY2015Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1681 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0182 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.44
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0243 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0749 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8529 pure
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2496000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2496000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2504000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
385000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
2504000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1734000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
770000
CY2015Q3 rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
3100

Files In Submission

Name View Source Status
0001193125-15-375630-index-headers.html Edgar Link pending
0001193125-15-375630-index.html Edgar Link pending
0001193125-15-375630.txt Edgar Link pending
0001193125-15-375630-xbrl.zip Edgar Link pending
d82772d10q.htm Edgar Link pending
d82772dex31.htm Edgar Link pending
d82772dex311.htm Edgar Link pending
d82772dex32.htm Edgar Link pending
d82772dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20150930.xml Edgar Link completed
rxii-20150930.xsd Edgar Link pending
rxii-20150930_cal.xml Edgar Link unprocessable
rxii-20150930_def.xml Edgar Link unprocessable
rxii-20150930_lab.xml Edgar Link unprocessable
rxii-20150930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending